Cannabinoid treatment for autism: a proof-of-concept randomized trial

2021210 citationsJournal Articlegold Open Access

Authors

Adi Aran · Shaare Zedek Medical Center

Moria Harel · Shaare Zedek Medical Center

Hanoch Cassuto · Shaare Zedek Medical Center

Lola Polyansky · Shaare Zedek Medical Center

Aviad Schnapp · Shaare Zedek Medical Center

Nadia Wattad · Shaare Zedek Medical Center

Dorit Shmueli ·

Abstract

This interventional study provides evidence that BOL-DP-O-01-W and BOL-DP-O-01, administrated for 3 months, are well tolerated. Evidence for efficacy of these interventions are mixed and insufficient. Further testing of cannabinoids in ASD is recommended. Trial registration ClinicalTrials.gov: NCT02956226. Registered 06 November 2016, https://clinicaltrials.gov/ct2/show/NCT02956226.

Topics & Keywords

Cannabis and Cannabinoid Research Autism Spectrum Disorder Research Genetics and Neurodevelopmental Disorders

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Molecular Autism

Volume 12, Issue 1, pp. 6-6

DOI: 10.1186/s13229-021-00420-2

Field-Weighted Citation Impact: 23.92